Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
14
×
indiana blog main
indiana top stories
14
×
life sciences
national blog main
boston blog main
clinical trials
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
biotech
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
national
eli lilly
amgen
cancer
drugs
teva pharmaceutical
regeneron pharmaceuticals
calcitonin gene-related peptide
cancer immunotherapy
chronic migraine
deals
food and drug administration
What
drug
14
×
fda
approval
new
won
approved
migraine
roundup
bio
cancer
class
developed
drugs
eli
lilly
patients
prices
annual
attention
biotech
companies
decades
friday
late
long
medicine
medicines
meeting
news
oks
oral
pain
potential
second
short
starts
therapy
time
trump
acute
Language
unset
Current search:
fda
×
drug
×
" indiana top stories "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details